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recognize epitopes in the proline-rich and C-terminal 
domains, and binding of 26 of these antibodies is strictly 
phosphorylation dependent. Thirteen antibodies showed 
inhibitory activity in a P301S lysate seeded in vitro tau 
aggregation assay. Two such antibodies, CBTAU-7.1 and 
CBTAU-22.1, which bind to the proline-rich and C-termi-
nal regions of tau, respectively, were characterized in more 
detail. CBTAU-7.1 recognizes an epitope that is similar to 
that of murine anti-PHF antibody AT8, but has different 
phospho requirements. Both CBTAU-7.1 and CBTAU-22.1 
detect pathological tau deposits in post-mortem brain tis-
sue. CBTAU-7.1 reveals a similar IHC distribution pat-
tern as AT8, immunostaining (pre)tangles, threads, and 
neuritic plaques. CBTAU-22.1 shows selective detection 
Abstract Several reports have described the presence of 
antibodies against Alzheimer’s disease-associated hyper-
phosphorylated forms of tau in serum of healthy individu-
als. To characterize the specificities that can be found, we 
interrogated peripheral IgG+ memory B cells from asymp-
tomatic blood donors for reactivity to a panel of phospho-
rylated tau peptides using a single-cell screening assay. 
Antibody sequences were recovered, cloned, and expressed 
as full-length IgGs. In total, 52 somatically mutated tau-
binding antibodies were identified, corresponding to 35 
unique clonal families. Forty-one of these antibodies 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00401-017-1705-y) contains supplementary 
material, which is available to authorized users.
 * Wouter Koudstaal 
 WKoudsta@its.jnj.com
1 Janssen Prevention Center, Janssen Pharmaceutical 
Companies of Johnson & Johnson, 3210, Merryfield Row, 
San Diego, CA 92121, USA
2 Department of Integrative Structural and Computational 
Biology, The Scripps Research Institute, La Jolla, CA 92037, 
USA
3 Janssen Prevention Center, Janssen Pharmaceutical 
Companies of Johnson & Johnson, Archimedesweg 6, 2333 
CN Leiden, The Netherlands
4 Department of Pathology, Amsterdam Neuroscience, 
VU University Medical Center, De Boelelaan 1117, 
Amsterdam 1081 HV, The Netherlands
5 Janssen Prevention Center, Janssen Pharmaceutical 
Companies of Johnson & Johnson, 2 Royal College Street, 
London NW1 0NH, UK
6 Skaggs Institute for Chemical Biology, The Scripps Research 
Institute, La Jolla, CA 92037, USA
7 Department of Neurology, Amsterdam Neuroscience, 
Academic Medical Center, Meidreefberg 9, Amsterdam 1105 
AZ, The Netherlands
8 Department of Epidemiology, Harvard T.H. Chan School 
of Public Health, 677 Huntington Avenue, Boston, MA 
02115, USA
9 Present Address: Janssen R&D US, 3210 Merryfield Row, 
San Diego, CA 92121, USA
10 Present Address: Informa, Pharma Intelligence, 3655 Nobel 
Drive, San Diego, CA 92122, USA
11 Present Address: TTP Labtech Inc, One Kendall Square, 
Cambridge, MA 02139-1594, USA
12 Present Address: Cidara Therapeutics, 6310 Nancy Ridge 
Drive, San Diego, CA 92121, USA
 Acta Neuropathol
1 3
of neurofibrillary changes by IHC. Taken together, these 
results suggest the presence of an ongoing antigen-driven 
immune response against tau in healthy individuals. The 
wide range of specificities to tau suggests that the human 
immune repertoire may contain antibodies that can serve as 
biomarkers or be exploited for therapy.
Keywords Alzheimer’s disease · Tau protein · Memory B 
cell · Monoclonal antibody
Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder, characterized by neuronal loss and cogni-
tive decline, which is rapidly becoming one of the leading 
causes of disability and mortality in the elderly [25, 26, 32, 
61]. Two major pathological findings in patients with AD 
are extracellular plaques formed by amyloid β (Aβ) pep-
tide [50, 51], and intracellular neurofibrillary tangles (NFT) 
containing aggregated tau protein [23, 36, 62]. Misfold-
ing and aggregation of tau are closely associated with the 
onset and progression of AD and other related neurodegen-
erative disorders, such as progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD) and frontotempo-
ral dementia (FTD), collectively referred to as tauopathies 
[41].
Tau is a highly soluble cytoplasmic protein expressed 
predominantly within the central nervous system (CNS) as 
six major isoforms, ranging in size from 352 to 441 amino 
acids. Under normal conditions, tau interacts with tubu-
lin and plays an important role in maintaining microtu-
bule architecture, thereby facilitating axonal transport and 
cytoskeletal remodeling [15, 21]. The tau protein sequence 
contains many potential phosphorylation sites, several of 
which have been shown to be important for modulating 
association with tubulin [8, 49]. Under pathogenic con-
ditions, however, increased phosphorylation (known as 
“hyperphosphorylation”) occurs at these sites, promoting 
microtubule dissociation, aggregation into paired helical 
filaments (PHFs) and subsequently insoluble neurofibril-
lary tangles (NFTs), and impairment of axonal transport 
and synaptic function, which collectively drive neuronal 
toxicity and cell death (reviewed in [35]). Analyses of 
NFTs isolated from human AD cortical tissue have identi-
fied several important phosphorylation sites closely associ-
ated with disease pathology [60].
Consistent with this observation, phospho-dependent 
murine anti-tau monoclonal antibodies (mAbs), including 
AT8 and AT100, which were obtained following immuni-
zation with PHFs of tau isolated from AD brain tissue, are 
uniquely able to differentially recognize disease-related 
tau deposits that occur in AD and other tauopathies [4]. 
Naturally occurring antibody responses against self-anti-
gens Aβ and tau have been reported in both healthy (non-
cognitively impaired) individuals and patients with AD 
[16, 18]. Recently, Dodel et al. have shown that antibod-
ies to Aβ that preferentially bind to early oligomeric forms 
can be used to improve cognition in animal models of AD 
[14, 43]. In another study, serum IgM and IgG antibodies 
to unphosphorylated and phosphorylated tau peptides were 
detected in a survey of AD individuals and age-matched 
controls [48], and antibodies to both types of tau have been 
found in intravenous immunoglobulin (IVIG) preparations 
[29, 54, 55]. Very little is understood regarding the signifi-
cance of these responses, although the presence of circulat-
ing Aβ and tau antibodies suggests that an ongoing autoim-
mune process may accompany AD.
In this study, we set out to assess what specificities of 
anti-tau antibodies could be recovered from human periph-
eral immune memory cells from apparently healthy donors. 
The completeness with which endogenous antibody rep-
ertoires can be described is proportionally related to the 
number of cells that can be interrogated. To screen immu-
nological memory responses to tau efficiently, we used a 
high-throughput, single-cell screening methodology that 
allows multiparametric selection and recovery of antibodies 
from enriched human memory B-cell populations. Using 
this highly sensitive method, which we call BSelex, we 
report the presence of circulating tau-specific, IgG+ mem-




Whole blood from healthy male and female donors 
was received from the San Diego Blood Bank (ages 
18–65 years) or The Scripps Research Institute (ages 
27–66 years). The use of samples from human volunteers 
followed protocols approved by the San Diego Blood Bank 
Review Board or The Scripps Research Institute Insti-
tutional Review Board depending on the donor source. 
Informed consent was obtained from the donors prior to 
the blood donation. Peripheral blood mononuclear cells 
(PBMCs) were isolated on Ficoll-Paque Plus (GE Health-
care) and cryopreserved at 50 million cells per ml in 90% 
FBS and 10% DMSO.
Peptide synthesis
In an effort to identify and recover naturally occurring 
human mAbs to tau, a panel of 122 overlapping, phos-
phorylated peptides spanning all putative phosphorylation 
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sites across human tau isoform 2N4R (tau441) was 
designed and synthesized. The overlapping tau phospho-
peptides ranged from 18 to 26 amino acids, containing 
either one or two phosphorylated residues to represent 
all possible combinations in regions with multiple puta-
tive phosphorylation sites. An amino-terminal biotin 
group was added during synthesis to facilitate capture by 
streptavidin in downstream experiments. An additional 
ten nonphosphorylated peptides spanning the length of 
tau441 were synthesized. Each peptide was synthesized 
by solid-phase chemistry with >95% purity (New Eng-
land Peptide, Inc.).
Generation of tau‑peptide baits and single cell sorting 
of tau‑specific memory B cells
Tau-peptide baits were prepared by mixing biotinylated 
peptides or biotin (negative control) with streptavidin-
APC or streptavidin-PE (Thermo Fisher) at a 35:1 molar 
ratio. The mixture was incubated overnight at 4 °C with 
gentle mixing and passed over a BioSpin 30 column (Bio-
rad) to remove free peptide or biotin. PBMCs from 3–4 
donors were thawed quickly, transferred to tubes contain-
ing prewarmed RPMI complete (RPMI, 10% heat-inacti-
vated FBS and 1% pen/strep), washed, and incubated sep-
arately at 37 °C for 16 h. The cells were collected and the 
B cells enriched by positive selection with CD22+ mag-
netic beads (Miltenyi Biotec). Cells were resuspended in 
Tris buffered saline, pH 7.4, containing 2 mM EDTA and 
0.25% bovine serum albumin, Fraction V (TBS buffer). 
An aliquot was removed for cytometer controls, and the 
extracellular markers IgG-FITC, CD19-PerCPCy5.5, and 
CD27-PECy7 (all from BD Biosciences) were added to 
the remaining cells. Ten million cells were removed for 
the negative control, and the biotin–streptavidin conju-
gates were added. The remaining cells were subsequently 
incubated with a pool of dual labeled peptide tetramers. 
The background and experimental tubes were incubated 
for 60 min at 4 °C with gentle mixing, washed and resus-
pended at 20 million cells per ml in TBS buffer. Prior to 
sorting, DAPI (Thermo Fisher) was added as a live/dead 
marker, and the cells were sorted on a Beckman Coulter 
MoFlo XDP. The negative control was used to determine 
nonspecific binding, to set the gates, and to determine 
the signal-to-noise ratio. Doublets and dead cells were 
excluded, and the CD19+, IgG+, CD27hi, and antigen 
double-positive cells were collected by single cell sort-
ing. Cells were collected directly into PCR plates con-
taining RT-PCR reaction buffer and RNaseOUT (Thermo 
Fisher). Plates were sealed with LMT-Aluma II covers 
(Phenix Research Products), centrifuged at 1000 rpm for 
1 min, and immediately frozen at −80 °C.
Recovery of heavy and light chain antibody genes 
from tau‑specific memory B cells
Heavy and light chain (HC/LC) antibody variable regions 
were recovered using a two-step PCR approach from sin-
gle-sorted memory B cells. Variable chain fragments were 
subsequently cloned and expressed as human IgG1. cDNA 
was first synthesized according to manufacturer’s instruc-
tions (Thermo Fisher, Superscript III First Strand Synthe-
sis kit), and 2.5 µl of cDNA sample was immediately used 
for step I HC/LC PCR reactions. A pool of forward prim-
ers specifically designed to the HC/LC antibody leader 
sequences and a single reverse primer specific to either 
Cγ, Cκ, or Cλ was used in the step I reaction. Step II PCR 
reactions were then prepared using 2.5 µl of the step I PCR 
product as template using a pool of forward primers spe-
cific to the HC and LC (κ and λ) framework 1 region and 
a pool of reverse primers specific to the junction region of 
each antibody chain. Step II PCR fragments, ranging from 
380 to 400 kb in size, were resolved and purified. Finally, 
the Step II fragments were linked via overlap exten-
sion PCR using a 1.8 kb linker product. Overlapped HC/
LC products were subsequently digested (XbaI and XhoI, 
New England Biolabs) and cloned into a dual-CMV–based 
human IgG1 mammalian expression vector (generated in 
house).
Recombinant IgG expression
Cloned anti-tau human mAbs were transiently transfected 
in human embryonic kidney 293-derived Expi293 cells 
(Thermo Fisher) and 72 h post transfection, cell media 
were harvested and centrifuged for 7 min at 1200 RPM. 
IgG was purified from the culture medium by standard Pro-
tein A affinity chromatography methods. IgGs were eluted 
from the protein A affinity column in 100 mM sodium cit-
rate buffer, pH 3.5 which was immediately exchanged for 
PBS. Antibodies were quantitated using Protein A sensor 
tips on the Octet Red384 (ForteBio). Each antibody was 
quality controlled by SDS-PAGE and size-exclusion chro-
matography, and was further confirmed for reactivity to 
cognate tau peptide by ELISA. For immunohistochemistry, 
mouse chimeric versions of CBTAU-7.1 and CBTAU-22.1 
were generated by replacing the human Fc with a murine 
Fc.
Aggregation assay
All animal work was done in accordance with local Insti-
tutional Animal Care and Use Committee guidelines and 
was reviewed and approved by the on-site Janssen R&D 
Institutional Animal Care and Use Committee. T43 trans-
genic mice express human 0N/4R tau containing the P301S 
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mutation from the Thy1 promoter [3]. At 5–6 months of 
age, aggregated, hyperphosphorylated tau accumulates in 
the brain and spinal cord of these mice. Spinal cord tissues 
were harvested from 6-month-old transgenic mice and snap 
frozen. Extracts were prepared by sonication of tissue in 
TBS with protease inhibitors (Roche Applied Science), and 
total protein was quantified using Pierce™ BCA Protein 
Assay Kit (Thermo Fisher). The biosensor cell line contain-
ing the cyan fluorescent protein (CFP)- and yellow fluores-
cent protein (YFP)-tagged tau repeat domain (RD) report-
ers was obtained from Marc Diamond [28]. For the assays, 
cells were plated at 10,000 cells/well in 96 well plates in 
130 µL DMEM (with 10% FBS, glutamax, and pen/strep) 
and allowed to attach for 24 h. Spinal cord extract from 
P301S tau transgenic mice was preincubated with vari-
ous concentrations of antibodies, or buffer alone, for 2 h 
at 37 °C before addition to the cell culture media. The 
tau extract/antibody mixtures were incubated on the cells 
for 72 h. For harvest and analysis, the cells were trypsin 
treated, washed, fixed in 2% paraformaldehyde for 10 min, 
and then resuspended in 1% FBS, 1 mM EDTA in HBSS 
for flow cytometry analysis on a MACSQuant 10. After gat-
ing on the cell population using FSC-SSC, and eliminating 
doublet cells, cells that were double-positive for CFP and 
YFP were selected for further analysis. From those cells, 
the percent of cells with a fluorescence resonance energy 
transfer (FRET) signal was measured. The FRET responses 
for each antibody, normalized against tau extract only, 
were collected from the results of several assays; results 
are shown for the highest concentration tested in two or 
more replicate assays. To facilitate the interpretation of the 
data, the results were expressed as the reduction in FRET 
response (i.e., 100—normalized FRET). Variation between 
assays was estimated (SD = 3.96%) and used to set a cut-
off (at 0% + 2 × SD = 7.92%). Ultimately, results were 
expressed as the mean reduction in FRET response (across 
all assays). For antibodies CBTAU-7.1, CBTAU-22.1 and 
AT8, a dose–response relationship was determined by 
serial dilution.
Reactivity of anti‑tau human mAbs to tau peptides 
by ELISA
Biotinylated tau peptides were captured on streptavidin-
coated plates (Thermo Fisher) at 1 µg/ml in TBS and 
incubated for 2 h. 96-well half-area ELISA plates (Cos-
tar) were coated overnight at 4 °C with goat anti-human 
Fab (2 µg/ml, Jackson ImmunoResearch) to measure total 
IgG. Bovine actin and an irrelevant (non-cognate) peptide 
chosen from the panel of 122 tau peptides were coated at 
1 µg/ml in TBS and used to confirm specificity of the puri-
fied mAbs. ELISA plates were washed four times with 
TBS/0.05% Tween 20 (TBS-T) and blocked with 2.5% 
BSA in TBS for 2 h. Purified IgGs were diluted to 5 µg/
ml in TBS/0.25% BSA and titrated (fivefold serial dilu-
tions) against peptides. Diluted samples were added to the 
plates and incubated for 2 h at room temperature. A human 
chimeric version of the PHF-tau-specific mouse antibody 
AT8 was generated by swapping out the mouse heavy and 
light chain constant regions for human IgG1 sequence. This 
AT8 chimeric antibody, which reacts to a phosphopeptide 
(Ser202/Thr205) spanning region 194–212, was used as 
a positive control at 1 µg/ml in ELISA assays when this 
phosphopeptide was tested. The plates were washed five 
times with TBS-T and secondary antibodies diluted in 
TBS/0.25% BSA were added and incubated at room temp 
for 1 h. Goat anti-human IgG F(ab’)2 (Jackson ImmunoRe-
search) was used at 1:2000 dilution and goat anti-mouse 
HRP (Jackson ImmunoResearch) was used at 1:4000 dilu-
tion. Following incubation, plates were washed four times 
in TBS-T and developed with Sure Blue Reserve TMB 
Microwell Peroxidase Substrate (KPL) for approximately 
2 min. The reaction was stopped by the addition of TMB 
Stop Solution and the absorbance at 450 nm was measured 
using an ELISA plate reader.
Western blot analysis
Reactivity to recombinant tau and PHF was tested by West-
ern blot analysis. Immunopurified PHF was provided by 
Steven Paul at Weill Cornell Medical College and prepared 
as previously described [22, 33]. Approximately 0.3 µg of 
PHF and 0.2 µg of recombinant tau (Sigma) were resolved 
on SDS-PAGE (4–12% Bis–Tris Novex NuPAGE gel; Inv-
itrogen) and subsequently transferred onto a nitrocellulose 
membrane. The membrane was blocked overnight in 1X 
TBS-T with 5% BSA (blocking buffer). Human chimeric 
anti-tau antibodies AT8 and htau10 were used as control 
antibodies at 25 µg/ml in 2.5% BSA in TBS-T and incu-
bated for 2 h at room temperature. The human chimeric 
version of htau10 was generated, as described above for 
chimeric AT8, by swapping out the mouse heavy and light 
chain constant regions for human IgG1 sequence. The 
membranes were then washed three times for 5 min each in 
TBS-T. Peroxidase AffiniPure goat anti-human IgG (Fc-γ 
fragment specific; Jackson ImmunoResearch) was used 
as secondary antibody at a 1:4000 dilution in 2.5% BSA 
in TBS-T and incubated for 1 h at room temperature. The 
membrane was washed three times for 5 min and developed 
using the Supersignal West Pico kit (Pierce). Images were 
obtained on the ImageQuant LAS-4000 (GE Healthcare).
Immunoprecipitation–mass spectrometry (IP‑MS)
To avoid contamination of the final eluate with IgG, a 
chemical crosslinker (BS3, Thermo Fisher) was employed 
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to covalently link the CBTAU mAbs to magnetic Protein A 
beads (Dynabeads, ThermoFischer Sci.). 25 μg of CBTAU 
was used per 100 μL bead suspension, with a crosslinker 
concentration of 0.5 mM. The prepared beads were added 
to 10 μL P301S transgenic mice brainstem homogen-
ate (total protein concentration 6.8 mg/mL, determined 
as described above) and incubated overnight at 4 °C after 
which flow-through was collected. The beads were exten-
sively washed to remove any nonspecific interactors and 
final elution was performed with LDS (Novex Nupage; 
Thermo Fisher) at 70 °C for 10 min. It should be noted that 
the affinities of phosphorylation-dependent antibodies 7.1 
and 22.1 are highly dependent on ionic strength and, for 
these IgGs, the protocol was carried out with buffers hav-
ing a tenth of the ionic strength of PBS. The flow-through, 
wash, and elution fractions were separated by SDS-PAGE 
(4–12% Bis–Tris Novex NuPAGE gel; Thermo Fisher) and 
analyzed by Western blot on PVDF membranes (iBlot; Inv-
itrogen) using total-Tau HT7 (Thermo Fischer) at a 1:1000 
dilution as primary antibody and 1:25,000 goat anti-mouse 
HRP conjugate (Invitrogen) as secondary antibody. ECL 
staining (GE Healthcare) was performed according to the 
manufacturer’s protocol. A separate elution was also per-
formed with 1% aqueous formic acid. Removal of acidic 
solution by refrigerated CentriVap benchtop vacuum con-
centrator (Labconco, US) has been followed by in-solution 
trypsin digestion of the eluted samples. The resulting tryp-
tic peptides were separated by reverse-phase chromatogra-
phy using Waters nano-ACQUITY UPLC pumps in com-
bination with a column switching system. Trapping of the 
peptides was performed using a Waters BEH C18 column 
(1.7 mm particles, 2.1 mm × 5 mm). Subsequently, pep-
tides were separated by a Waters UPLC BEH C18 analyti-
cal column (1.7 mm particles, 1 mm × 100 mm) using gra-
dient elution. Mass and fragmentation data of the separated 
peptides were recorded with a Waters Xevo-G2S QTof 
Mass Spectrometer operating in the MSe mode. Recorded 
data has been analyzed by the Waters BiopharmaLynx soft-
ware (version 1.3.3). In addition, manual inspection of the 
spectra was performed using the MassLynx Software (ver-
sion 4.1) to confirm the identity of peptides.
Peptide mapping by ELISA
Streptavidin-coated 96-well plates (Thermo Fisher) were 
washed four times with TBS-T, followed by incubation 
overnight at 4 °C with 400 nM of the panel of tau-specific 
biotinylated peptides in Table S3. Plates were washed four 
times the following day with TBS-T and subsequently 
blocked for 1 h with 2.5% BSA in TBS. Human anti-tau 
antibodies were added at 2 µg/ml in TBS/0.25% BSA for 
1 h at room temperature. Plates were washed four times 
with TBS-T, followed by incubation with goat anti-human 
IgG F(ab’)2 (Jackson ImmunoResearch) at 1:2000 dilution 
in TBS/0.25% BSA for 1 h at room temperature. Plates 
were washed six times in TBS-T and developed with Sure 
Blue Reserve TMB Microwell Peroxidase Substrate (KPL) 
for approximately 90 s. The reaction was stopped by addi-
tion of TMB Stop Solution, and absorbance at 450 nm was 
measured using an ELISA plate reader. Nonspecific bind-
ing of the human anti-tau mAbs was determined by meas-
uring binding to non-peptide coated wells and subtracted 
for each antibody.
Qualitative association and dissociation measurements 
by Octet biolayer interferometry
The relative binding of CBTAU-7.1 and CBTAU-22.1 
mAbs to tau peptides corresponding to their assumed 
epitope was assessed by biolayer interferometry (Octet 
Red 384) measurements (ForteBio) [11]. Biotinylated tau 
peptides were immobilized on Streptavidin (SA) Dip and 
Read biosensors for kinetics (ForteBio). Real-time binding 
curves were measured by applying the sensor in buffer con-
taining 100 nM CBTAU mAbs. The immobilization of pep-
tides to sensors and the association were followed in differ-
ent ionic strength buffers containing 10% kinetic buffer. To 
induce dissociation, the biosensor containing the mAb-tau-
peptide complex was immersed in kinetic buffer (ForteBio) 
without antibody. The relative association and dissociation 
kinetic curves were compared to qualitatively assess the 
efficiency of CBTAU binding to peptides with different 
phosphorylation patterns under different conditions.
Affinity measurements by isothermal titration 
calorimetry (ITC)
The affinities of AT8, CBTAU-7.1, and CBTAU-22.1 for 
their corresponding tau peptides were determined in solu-
tion on a MicroCal Auto iTC200 system (Malvern). Pep-
tides at concentrations of ~30 µM (AT8), ~40 µM (CBTAU-
7.1), and ~40 µM (CBTAU-22.1) were titrated in 20 steps 
of 2 µl per step in identical buffers containing 140 µM AT8, 
200 µM CBTAU-7.1 and 200 µM CBTAU-22.1, respec-
tively. The thermodynamic parameters and the equilibrium 
dissociation constants, Kd, were determined upon fitting 
the ITC data to a model assuming a single set of binding 
sites corresponding to a mAb:tau peptide = 1:2 binding 
model.
Expression of recombinant CBTAU‑7.1 
and CBTAU‑22.1 Fabs for crystallization
To express Fab fragments for crystallization, the hinge, 
CH2, and CH3 sequences of the cloned CBTAU-7.1 and 
CBTAU-22.1 IgGs in the dual-CMV-based human IgG1 
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mammalian expression vector were removed and a His6 
tag added to the C-terminus of CH1. The Fab fragments 
were produced by transient transfection of FreeStyle 
293-F cells and purified using an Ni–NTA column fol-
lowed by size-exclusion chromatography using a Super-
dex 200 column (GE Healthcare).
Crystallization, data collection, and structure 
determination
Crystallization of CBTAU-7.1 and CBTAU-22.1 Fabs 
was performed using the high-throughput automated 
CrystalMation robot (Rigaku) at The Scripps Research 
Institute (TSRI). Following optimization, CBTAU-7.1 
crystals were obtained using the vapor diffusion sitting 
drop method at 20 °C by mixing 0.1 µl of the concen-
trated protein (8 mg/ml) in 20 mM Tris, pH 8.0, 150 mM 
NaCl, 0.02% NaN3 with 0.1 µl of a reservoir solution 
containing 20% (w/v) polyethylene glycol (PEG) 3350, 
0.2 M ammonium dihydrogen phosphate. Before data 
collection, the CBTAU-7.1 crystals were soaked for a 
few seconds in the reservoir solution supplemented with 
15% (v/v) glycerol and then flash-frozen in liquid nitro-
gen. CBTAU-22.1 crystals were obtained using the same 
method at 20 °C by mixing 0.1 µl of the concentrated 
protein (12 mg/ml) in 20 mM Tris, pH 8.0, 150 mM 
NaCl, 0.02% NaN3 in the presence of 0.9 mM of tau-pep-
tide 412SSTG(pS)IDMVD(pS)PQLATLA429 (pS, phos-
phorylated serine) with 0.1 µl of a reservoir solution con-
taining 0.1 M citrate buffer, pH 4.0, 2.4 M (NH4)2SO4. 
Before data collection, the CBTAU-22.1 crystals were 
soaked for a few seconds in the reservoir solution sup-
plemented with 25% (v/v) glycerol and then flash-frozen 
in liquid nitrogen. The X-ray structures of the CBTAU-
7.1 and CBTAU-22.1 Fabs were determined by molecu-
lar replacement (MR) using the program Phaser [42]. The 
initial models for MR of CBTAU-7.1 Fab were the Fab 
N12-I2 light chain (PDB code 3QEG) and Z13E1 Fab 
heavy chain (PDB code 3FN0). The initial models for 
MR of CBTAU-22.1 Fab were the Fab MSL-109 light 
chain (PDB code 4LRI) and putative VRC01 germline 
precursor Fab heavy chain (PDB code 4JPK). One Fab 
was found in the asymmetric unit in both structures. Ini-
tial rigid body refinement was performed using program 
Phenix [1]. Further model rebuilding was performed 
using the graphics program Coot [17] and refined with 
Phenix. As no electron density for bound peptide was 
present in the CBTAU-22.1 electron density, the peptide 
ligand was presumably outcompeted by the high molarity 
of sulfate ions from the 2.4 M ammonium sulfate in the 
crystallization condition. Final refinement statistics are 
summarized in Table S4.
Post‑mortem human brain tissue
Brain samples were obtained from The Netherlands Brain 
Bank (NBB), Netherlands Institute for Neuroscience, 
Amsterdam (open access. www.brainbank.nl). All materi-
als were collected from donors for or from whom written 
informed consent for a brain autopsy and the use of the 
material and clinical information for research purposes had 
been obtained by the NBB. Dementia status at death was 
determined on the basis of clinical information available 
during the last year of life and neuropathological diagno-
sis using histochemical stains (haematoxylin and eosin, 
Bodian and/or Gallyas silver stains [59], methenamine sil-
ver stain) and immunohistochemistry for Aβ, p-tau (AT8), 
α-synuclein, TDP43, and P62. Analysis of formalin-fixed 
and paraffin-embedded tissue from different parts of the 
brain was performed, including the frontal cortex (F2), 
temporal pole cortex, parietal cortex (superior and infe-
rior lobule), occipital pole cortex, amygdala, and the hip-
pocampus, essentially CA1 and entorhinal area of the para-
hippocampal gyrus. Staging of pathology was evaluated 
according to a modified assessment of Braak and Alafuzoff 
and the Aβ staging of Thal [2, 9, 57]. For cases with and 
without clinical neurological disease, diagnosis was pro-
cessed identically. Brain tissue samples were either for-
malin-fixed and paraffin embedded or snap frozen (liquid 
N2). For this study, brain tissue was obtained from the hip-
pocampus (middle part at the level of the lateral geniculate 
body), caudate nucleus, the frontal cortex (F2, premotor 
dorsal, caudal), and the mid-temporal cortex.
Immunohistochemistry
Slide-mounted immunohistochemistry: Sections (5 μm 
thick) from formalin-fixed paraffin-embedded tissue 
were mounted on Superfrost Plus tissue slides (Menzel-
Gläser, Germany) and dried overnight at 37 °C. Sections 
were deparaffinized and subsequently immersed in 0.3% 
H2O2 in phosphate-buffered saline (PBS) for 30 min to 
quench endogenous peroxidase activity. Sections were 
treated in sodium citrate buffer (10 mM sodium citrate, 
pH 6.0) heated by autoclave (20 min at 130 °C) for anti-
gen retrieval. Between the subsequent incubation steps, 
sections were washed extensively with PBS. Primary anti-
bodies were diluted in antibody diluent (Immunologic) and 
incubated overnight at 4 °C. Secondary EnVisonTM HRP 
goat anti-rabbit/mouse antibody (EV-GαMHRP, DAKO) 
was incubated for 30 min at RT. 3,3-Diaminobenzidine 
(DAB; DAKO) was used as chromogen. Sections were 
counterstained with haematoxylin to visualize the nuclei of 
the cells, dehydrated and mounted using Quick-D mount-
ing medium (BDH Laboratories Supplies, Poole, Eng-
land). To remove phosphate groups from phosphorylated 
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proteins prior to IHC detection, sections were treated with 
alkaline phosphatase solution before incubation with pri-
mary antibodies. Before incubation, sections were washed 
with Tris–HCl, pH 8.0 and incubated in freshly prepared 
alkaline phosphatase solution (100 mM Tris–HCl, pH 8.0 
supplemented with 130 units/mL calf intestinal alkaline 
phosphatase (New England Biolabs), 1 mM phenylmethyl-
sulfonyl fluoride (PMSF) (Sigma), 10 µg/mL pepstatin 
(Sigma), 10 µg/mL leupeptin (Sigma)) for 2.5 h at 37 °C. 
Sections were rinsed twice with 100 mM Tris–HCl, pH 
8.0 for 3 min at RT prior to detection with primary anti-
bodies. Double labeling of paraffin-embedded tissue sec-
tions was carried out as follows. Deparaffinized sections 
were subjected to wet autoclave antigen retrieval in citrate 
buffer and incubated overnight with chimeric CBTAU-7.1 
(2.5 μg/ml) or chimeric CBTAU-22.1 (10 μg/ml). After 
thorough rinsing, goat-anti-mouse-EnVision+™ HRP-
labelled secondary antibodies (DAKO) were incubated 
at RT for 30 min. DAB chromogen was used to visualize 
HRP-labeled structures. An additional microwave heating 
step in citrate buffer was performed after the DAB visu-
alization for 10 min. This additional heating step removes 
all immune complexes, yet DAB precipitates remain. 
To block nonspecific binding of the secondary antibod-
ies, sections were incubated with 2% normal rabbit serum 
(DAKO) at RT for 10 min before they were incubated with 
AT8 (Thermo Fisher, 0.25 μg/ml) or chimeric CBTAU-
7.1 (2.5 μg/ml) at RT for 1 h. After washing, secondary 
biotinylated-rabbit-anti-mouse (DAKO) antibodies were 
allowed to bind for 45 min at RT. The sections were then 
incubated with alkaline phosphatase (AP) labeled streptavi-
din (Roche Applied Science) for 60 min. Liquid permanent 
red (LPR, DAKO) substrate was used to detect AP-labeled 
structures. Sections were counterstained with haematoxylin 
prior to permanent mounting in Aquatex (Merck, Darm-
stadt, Germany). Double labeling was analyzed and photo-
graphed by the use of a nuance multispectral imager (Perki-
nElmer, Waltham, MA, USA).
Free-floating (immuno) histochemistry: Formalin-fixed 
brain tissue was rinsed in distilled water and impregnated 
in increasing concentrations sucrose (10-20-30% in dis-
tilled water). When the tissue sank in the sucrose solution 
(after 2–4 days), it was transferred to the following sucrose 
concentration. After passing through the three concen-
trations the prepared material was stored at −20 °C until 
further use. Thirty µm-thick sections were transferred in 
wells of a 24-well culture plate (Sigma) and rinsed with 
PBS. Endogenous peroxidase activity was blocked by incu-
bating the sections 30 min in PBS containing 0.3% H2O2. 
Subsequently sections were rinsed in washing buffer: 0.5% 
Tween20 (Sigma), 0.25% Triton X-100 (Merck), 0,1% 
gelatin from cold water fish skin (Sigma) and 1% bovine 
serum albumin (BSA, Roche) in PBS, and exposed to heat 
induced antigen retrieval using citrate buffer (pH 6.0) at 
80 °C. After allowing the heated sections to regain RT, 
sections were rinsed in washing buffer and incubated with 
blocking buffer: 2% normal rabbit serum (Dako) in wash-
ing buffer. The blocking buffer was replaced by blocking 
buffer containing primary antibodies: CBTAU7.1 (5 µg/
mL), CBTAU22.1 (5 µg/mL) and AT8 (0.25 µg/mL). The 
following day sections were thoroughly rinsed with wash-
ing buffer and incubated with HRP conjugated rabbit-anti-
mouse antibody (DAKO) for 1 h. After extensive washing 
DAB was used as chromogen. Sections were counterstained 
with haematoxylin, dehydrated and mounted using Quick-
D mounting medium.
For the gallyas silver staining 30 µm-thick sections were 
rinsed in distilled water and incubated in 5% periodic acid 
for 30 min at RT, followed by an incubation in silver iodide 
solution (4% sodium hydroxide, 10% potassium iodide 
and 0.35% silver nitrate in distilled water) for 30 min at 
RT. Subsequently, sections were washed in 0.5% acetic 
acid and developed with developer working solution (10 
volumes 5% sodium carbonate solution, 3 volumes solu-
tion 0.2% ammonium nitrate, 0.2% silver nitrate and 1% 
Tungstosilicic acid solution, and 7 volumes 0.2% ammo-
nium nitrate, 0.2% silver nitrate, 1% Tungstosilicic acid 
and 0.3% formaldehyde solution). After color development, 
sections were rinsed in 0.5% acetic acid, after which sec-
tions were incubated in 5% sodium thiosulphate and rinsed 
in distilled water. Stained sections were mounted on coated 
glass slides (Menzel-Gläser) and dried for at least 2 h at 
37 °C. Subsequently, sections were fixed in 70% ethanol 
for 10 min, counterstained with hematoxylin, dehydrated, 
and mounted with Quick D mounting medium.
Data deposition The atomic coordinates and structure 
factors of the CBTAU-7.1 Fab and CBTAU-22.1 Fab have 
been deposited in the Protein Data Bank, www.rcsb.org 
(PDB ID codes 5V7R and 5V7U).
Results
Blood samples from healthy donors between the ages of 
18 and 66 years were screened for the presence of memory 
B cells reactive to tau using the BSelex method (Fig. 1a). 
Prior to sorting, B cells from individual donors’ PBMCs 
were enriched by CD22 positive selection and then tagged 
with fluorescently labeled CD19, CD27, and IgG antibod-
ies to identify the peripheral IgG memory B cell popula-
tion. After processing, we recovered 150,000 cells per 
donor sample on average, consistent with previous observa-
tions of about 0.05% of the PBMCs harvested [64]. Not-
withstanding, based on these results, and to maximize the 
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probability of identifying specific tau-reactive antibodies 
in the memory compartment, we increased the number of 
cells interrogated in each sort by pooling multiple (3 or 4) 
donor samples. We used a comprehensive panel of 122 tau 
peptides as antigenic probes. These peptides were synthe-
sized, such that all well-characterized phosphorylation sites 
were represented, and when potential sites occurred within 
seven amino acids of each other, all combinations of singly 
and doubly phosphorylated peptides were included (Fig. 
S1). Since technical limitations prevented the use of the 
entire panel of tau phosphopeptides within each sort, we 
employed a strategy whereby varying subsets of peptides, 
up to 10 at a time, were selected for individual sorts in such 
a way that all peptides were eventually used in two or more 
sorts. As identification of rare specificities can easily be 
overwhelmed by poor separation of specific and nonspe-
cific signals, we utilized polyvalent displays of tau peptide 
labeled with either APC or PE and gating on the double-
positive population (PE+, APC+) to increase the signal-
to-noise ratio and recover tau-specific B cells (Fig. 1b). 
Antibody heavy and light variable chain sequences were 
recovered from single cells, and full-length IgGs were 
cloned and expressed. In total, samples from 120 healthy 
donors were screened and 52 unique tau-binding antibodies 
were identified from the memory B cell donor pools. By 
back calculating, using the frequency of antigen-positive 
cells identified and taking into account sorting losses, clon-
ing inefficiencies and reconfirmation rate, we estimate a 
median frequency of 12.5 potential hits per 1 × 106 mem-
ory B cells examined across all sorts (Fig. 1c).
Antibody sequences recovered from tau binders were 
analyzed for heavy and light chain germline usage and fre-
quency of variable region somatic mutations. Sequence and 
germline usage information allowed assignment of the 52 
tau antibodies to 35 unique clonal families (Fig. 2a, Table 
S1). Germline analysis showed a higher than expected pref-
erence (81%) for IGHV3, compared to a reported average 
of 35% of the naïve B cell population [20]. Primer sets 
used to clone antibody genes were previously confirmed to 
amplify all major heavy and light chain germline genes, so 
the abundance of VH3 heavy chain antibodies is unlikely 
to be the result of primer bias. Both heavy and light chain 
sequences revealed a number of somatic mutations, with 
median frequencies of 20 and 12.5 nucleotide substitutions 
for the heavy and light chain variable regions, respectively 
(Fig. 2b). The distribution of anti-tau antibodies into clonal 
Fig. 1  Recovery of naturally occurring monoclonal antibodies to 
pathogenic tau from asymptomatic individuals. a BSelex method 
used to recover tau-specific memory B cells. PBMCs were prepared 
from asymptomatic (non-AD) blood bank donors, and mature CD22+ 
B cells were positively selected with magnetic beads. Viable cells 
were stained with IgG-FITC, CD19-PerCPCy5.5, and CD27-PECy7, 
and with labeled peptide antigens and single-cell sorted on a Beck-
man Coulter MoFlo XDP. Antibody heavy and light variable chain 
sequences were recovered from single cells, cloned and expressed as 
full-length IgGs. b Polyvalent displays of tau phosphopeptides were 
labeled with APC or PE and gated on the double-positive population 
(PE+, APC+) to increase the signal-to-noise ratio. Memory B cells 
that showed reactivity to both APC- and PE-labeled peptides simul-
taneously were sorted as single cells into 96-well plates for further 
processing and recovery of IgH and IgL genes. Shown is a repre-
sentative flow cytometric graph. c Estimated frequency of tau-specific 
B cells (Hits) per 106 memory B cells interrogated in the different 
sorts. Based on sorting losses (gated cells not being deposited), clon-
ing efficiency (ability to recover both antibody heavy and light chains 
from single cells), and reconfirmation rate (whether the cloned anti-
body showed tau binding), we estimate that on average there were 
12.5 potential hits per 1x106 CD22+ CD19+CD27+IgG+ memory B 
cells examined across all sorts. The horizontal line indicates median, 
and error bars the inter-quartile range
Fig. 2  Sequence analysis of recovered anti-tau monoclonal antibod-
ies. a Phylogenetic analysis of recovered tau antibody heavy and light 
chain variable regions was performed using the neighbor-joining 
algorithm (Jukes Cantor model) and illustrated as a circular tree. b 
Number of somatic mutations in VH and VL genes in 52 antibodies 
analyzed from IgG+ memory B cells with reactivity to tau. Muta-
tions and identification of the closest germline were determined using 
IgBlast and IMGT databases. The horizontal line indicates median 
and error bars the inter-quartile range
Acta Neuropathol 
1 3
families and the high degree of somatic mutations suggest 
that these antibodies share characteristics consistent with 
those evolving from ongoing antigen-driven responses.
Since memory B cell selections were performed using 
pools of peptides, an ELISA-based binding assay with 
each peptide was performed to identify the peptide-binding 
partner. For each antibody recovered, we were able to con-
firm binding to a single peptide from the initial bait pool, 
which provided an indication of its binding region (Table 
S1). Although we exploited the use of phosphopeptides to 
screen for tau-specific memory B cells, it remains possible 
that antibody binding can occur independently of phospho-
rylation. To assess whether antibody binding was depend-
ent on peptide phosphorylation, hits were also screened 
against nonphosphopeptides spanning the corresponding 
regions. While half of the 52 antibodies recovered bound 
only to the phosphorylated cognate peptide, the other half 
reacted to both the phosphorylated and unphosphorylated 
peptides containing their epitopes (Table S1). Forty-one of 
the recovered antibodies recognize epitopes in the proline-
rich (32 out of 52) and C-terminal (9 out of 52) domains, 
in accordance with the fact that—due to the distribution of 
phosphorylation sites on the tau protein—most of the pep-
tides used as bait cover these regions (Fig. S1).
We next assessed the ability of the antibodies to block 
tau aggregate seeding activity present in P301S spinal 
cord lysates. This cell-based biosensor assay was adapted 
from Yanamandra et al. and is based on the expression of 
the microtubule repeat domains of tau (aa 243–375) with 
a D280K mutation [65]. The repeat domains are fused 
either to yellow or cyan fluorescent protein and uptake of 
exogenous tau aggregates into the cells results in aggre-
gation of the tau fusion proteins, which is detected by 
FRET. The PHF-tau-specific mouse antibody AT8 [7] and 
an anti-RSV-G specific antibody generated in house were 
used as positive and negative controls, respectively. For 
this qualitative assessment, we determined whether or not 
activity was detected at the highest tested concentration 
of each antibody. Since this concentration was dependent 
on the antibody expression of the batch produced, which 
varied among the different antibodies, there may be some 
false-negatives among antibodies that did not express well. 
Nevertheless, inhibitory activity was detected for 13 of the 
antibodies (Fig. 3a). Interestingly, this was the case for all 
(8 out of 8) phospho-dependent antibodies binding to the 
C-terminus of tau. In addition, some phospho-dependent 
as well as phospho-independent antibodies that bind in the 
center region of tau—the region containing the microtubule 
binding domains and forming the core of tau filaments—
were also able to reduce tau aggregate seeding in vitro 
(Fig. 3b). Of note, none of the human antibodies showed 
more inhibitory activity than AT8, despite considerably 
higher concentrations tested (Fig. 3a). Titration of two of 
the antibodies, CBTAU-7.1 and CBTAU-22.1, confirmed 
the lower potency of the human antibodies in this assay 
(Fig. S2).
As representatives for phospho-dependent antibod-
ies showing activity in the in vitro tau aggregate seeding 
assay and binding to the proline-rich and the C-terminal 
domains, respectively, CBTAU-7.1 and CBTAU-22.1, 
were characterized further. The peptide reactivity observed 
using ELISA was extended by measuring binding to full-
length recombinant tau (rTau) and PHF from human AD 
Fig. 3  Antibody activity in an in vitro tau aggregation assay in rela-
tion to binding region and phospho-dependency. a Reduction in 
FRET signal of the highest tested concentration for each antibody. 
The names of antibodies that showed above-cutoff activity are indi-
cated. Murine anti-tau antibody AT8 and anti-RSV-G antibody, 
RSV4.2, were included as positive and negative controls, respectively. 
Dotted line indicates a threshold (0% reduction + 2 × SD) below 
which measured activity is considered background. b Schematic 
showing the relative positions along tau isoform 2N4R of the tau pep-
tides used to recover each of the 52 anti-tau antibodies. Highlighted 
(red) are the peptides recognized by those antibodies that show activ-
ity in the aggregation assay and the names of the respective antibod-
ies are indicated. Cognate peptides of antibodies whose binding is 
dependent on phosphorylation are depicted above the representation 
of the tau isoform, while those of antibodies that bind to both phos-
phorylated and unphosphorylated peptides are depicted below the 
representation of the tau isoform. N1 and N2 indicate acidic inserts, 




cortical tissue by Western blot. Consistent with previous 
reports, AT8 showed strong immunoreactivity to PHF (giv-
ing the characteristic three-band staining), but not to rTau 
(Fig. 4a), due to the absence of phosphorylation on the E. 
coli expressed protein. In contrast, the pan-tau antibody 
htau10 [46] recognized both PHF and rTau. Similar to AT8, 
CBTAU-7.1 and CBTAU-22.1 recognized PHFs, but no 
binding to rTau was observed, supporting the observation 
that binding of these antibodies requires phosphorylation 
of one or more residues within the epitope. Furthermore, 
immunoprecipitation experiments using brain samples 
from P301S mice confirmed the ability of CBTAU-7.1 and 
CBTAU-22.1 to bind tau under native conditions (Fig. 4b; 
Table S2).
To explore the interactions of the antibodies with tau, 
we mapped the epitopes using sets of differentially phos-
phorylated peptides. AT8 has previously been reported to 
recognize an epitope on tau between residues 194 and 212, 
phosphorylated at S202 and T205 [47] and also at S208, as 
reported more recently [39]. Our peptide mapping results 
confirmed the importance of phosphorylation of S202 and 
T205 for AT8 binding (Table S3). Antibody CBTAU-7.1 
was mapped exclusively to the same peptide region as AT8 
(Table S3), but its affinity for the doubly phosphorylated 
peptide at positions S202 and T205 was much lower than 
that of AT8 (5.8 µM vs 87.5 nM, Fig. S3). However, binding 
of CBTAU-7.1 appeared to be more promiscuous involving 
not only phospho-residues on positions S202 and T205, 
but also combinations of S198 + S202, S198 + T205, 
S199 + T205, and possibly Y197 + T205 (Table S3). That 
the epitopes to which CBTAU-7.1 and AT8 bind are similar 
but not identical is also clear from biolayer interferometry 
measurements, which confirmed that CBTAU-7.1 was able 
to bind to peptide phosphorylated at positions S198 and 
S202, whereas AT8 was not, and furthermore showed that 
phosphorylation of a third residue (S198), in addition to 
S202 and T205, increased binding by CBTAU-7.1 but had 
no effect on AT8 binding (Fig. S4).
Binding of CBTAU-22.1 was found to be depend-
ent on phosphorylation of S422 (Table S3) and, as seen 
for CBTAU-7.1, affinity for phosphorylated peptide was 
modest (32.7 µM) (Fig. S2). Binding of both CBTAU-7.1 
and CBTAU-22.1 was notably affected by ionic strength 
(Fig. S5), which suggests that binding is stabilized by 
ionic interactions with involvement of phospho groups in 
both cases. This notion is supported by crystal structures 
of CBTAU-7.1 and CBTAU-22.1 Fabs (Table S4) which 
we determined at 2.30 and 1.64 Å resolution, respec-
tively. For CBTAU-7.1, the framework and all CDR 
loops can be fully modeled into the high-quality electron 
density map. The CBTAU-7.1 combining site is lined 
mostly by hydrophilic and aromatic residues (Fig. 4c). 
Basic residues are prevalent in and around the antibody 
binding site: Arg96 from light chain (Kabat numbering) 
and Arg50 from heavy chain are in the combining site 
and Arg94 and Arg96 from heavy chain line the rim of 
the presumed binding pocket (Fig. 4c). These positively 
charged residues create basic electrostatic pockets on the 
antibody surface (Fig. 4e) that could play an important 
role in the phosphopeptide recognition. In Fab CBTAU-
22.1, the CDR loop residues also fit the electron density 
very well, except for the more flexible CDR L1 resi-
dues 27d, 27e, 28 and 29. A disulfide bond is formed in 
CDR H3 between Cys97 and Cys100b (Fig. 4d). Simi-
lar to CBTAU-7.1, three basic residues, Arg50 and Lys58 
from the heavy chain, and Arg27e from the light chain, 
are present in the antibody combining site, which dis-
play very strong positive electrostatic potential (Fig. 4f). 
Interestingly, two sulfates from the crystallization buffer 
can be modeled into electron density in the highly basic 
combining site. One sulfate SO4-1 hydrogen bonds with 
His35 and the main-chain amides from His96 and Cys97 
of heavy chain, with Arg27e in close proximity. Another 
sulfate SO4-2 forms a salt-bridge with Arg50 of heavy 
chain and hydrogen bonds with Thr94 of the light chain, 
with Lys58 of the heavy chain nearby. Furthermore, 
Lys58 and Arg27e are somatic mutations from the ger-
mline V-genes. Thus, these sulfate interactions and the 
strong basic nature of the combining site (Fig. 4f), likely 
explain the recognition of the phosphoryl groups in the 
tau phosphopeptides.
To further assess the specificity of the anti-tau anti-
bodies, we conducted immunohistochemical staining on 
post-mortem brain tissue. CBTAU-7.1 and CBTAU-22.1 
detected pathological tau structures in AD brain tissue, but 
not non-AD brain tissue. Comparable results were obtained 
when paraffin-embedded, formalin-fixed and fresh-frozen 
tissues were examined using either free-floating or slide-
mounted immunohistochemistry and with or without anti-
gen retrieval steps. Optimal immunohistochemical detec-
tion (i.e., staining of pathological tau without staining of 
the parenchyma) was obtained at 5 μg/ml for CBTAU-7.1 
and CBTAU-22.1, whereas a concentration of 0.25 μg/ml 
was optimal for AT8 (Fig. S6). Observed immunoreactiv-
ity with CBTAU-7.1 and CBTAU-22.1 was compared with 
Gallyas staining for neurofibrillary changes and detec-
tion of p-tau using the AT8 antibody (Fig. 5). CBTAU-
7.1 showed staining of neurofibrillary tangles, pretangles, 
neuritic plaques and neuropil threads that was compara-
ble to AT8. CBTAU-22.1 also showed immunostaining of 
neurofibrillary tangles and neuritic plaques, but less neu-
ropil threads compared to AT8 and CBTAU-7.1. Overall, 
the detection of p-tau with CBTAU-22.1 was comparable 
with the detection of neurofibrillary changes observed with 
Gallyas staining. Pretreatment of AD brain slides with 
alkaline phosphatase prohibited the detection of p-tau with 
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Fig. 4  Specificity and structural characterization of human anti-tau 
antibodies. a Reactivity of AT8 (phospho-dependent), htau10 (non-
phospho–dependent), CBTAU-7.1 and CBTAU-22.1 to PHF and 
recombinant human tau-441 by Western blot. Triple bands charac-
teristic of PHF-tau correspond to approximately 68, 64, and 60 kDa. 
b Western blot of flow-through (FT), wash (Wash) and eluate (Elu-
tion) fractions of immunoprecipitation (IP) of P301S transgenic mice 
brainstem homogenate with CBTAU-7.1 (left) and CBTAU-22.1 
(right), as well as untreated P301S (Total) homogenate. The blot 
was stained with total-Tau antibody HT7. Total volumes of all sam-
ples were kept similar to enable comparison of concentrations. (c 
and d) Crystal structures of the combining sites of CBTAU-7.1 and 
CBTAU-22.1 Fab, respectively. Some solvent-exposed CDR residues 
in and around the antibody combining site are shown in cyan carbon 
atoms (light chain) and green carbon atoms (heavy chain). Two sul-
fates were modeled in the combining site of CBTAU-22.1 (d). (e and 
f) Electrostatic potential surfaces in and around the combining sites 
of CBTAU-7.1 Fab and CBTAU-22.1 Fab, respectively. Electrostatic 
surface potentials were calculated using the APBS program [5]. Neg-
atively charged regions are red, positively charged regions are blue, 
and neutral regions are white (−15 to 15 KbT/ec potential range). 
Both CBTAU-7.1 and CBTAU-22.1 Fab exhibit highly positively 
charged surfaces in their combining sites
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CBTAU-7.1 and CBTAU-22.1 almost completely, confirm-
ing the high selectivity for phosphorylated epitopes on tau 
(Fig. S7).
Immunostaining on temporal cortex and hippocampus 
slides of a cohort (n = 36) with different Braak stages 
ranging from I to VI showed that immunoreactivity of 
both CBTAU-7.1 and CBTAU-22.1 is Braak stage-depend-
ent, similar to AT8 (Fig. S8). Neuronal immunostaining 
with the different antibodies was compared using double-
immuno-labeling (Fig. 6). AT8 and CBTAU-7.1 showed 
Fig. 5  Overview of the 
pathological structures detected 
with Gallyas staining, AT8, 
CBTAU-7.1 and CBTAU-22.1. 
Staining was performed on 
30 μm-thick, formalin-fixed, 
free-floating sections (temporal 
cortex, Alzheimer’s disease 
case, Braak VI). a, b Gallyas 
staining showing neurofibrillary 
changes. c, d AT8 immunostain-
ing (0.25 μg/ml); e, f Immu-
nostaining with CBTAU-7.1 
(5 μg/ml). g, b Immunostaining 
with CBTAU-22.1 (5 μg/ml). 
Immunohistochemical detection 
with DAB (brown) and nuclei 
counterstained with haematoxy-
lin (blue). Bar represents 50 μm
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co-labeling of individual neurons. However, a complete 
overlap in immunostaining was not observed (Fig. 6b, 
d, f). Using the co-immunolabeling protocol, the overall 
detection of tau structures with AT8 was reduced, sug-
gesting that an incubation of CBTAU-7.1 in the first step 
of the co-immunolabeling experiment reduced subsequent 
immunodetection with AT8. CBTAU-22.1 immunostained 
fewer neurons compared to AT8. In addition to neurons that 
showed co-localization of AT8 and CBTAU-22.1 (Fig. 6i, 
l, o), neurons immunopositive for AT8 and negative for 
CBTAU-22.1 were observed (Fig. 6h, k, n). Co-labeling of 
CBTAU-7.1 and CBTAU-22.1 also showed partial overlap. 
Only some of the neurons that showed strong immunore-
activity with CBTAU-7.1 were detected with CBTAU-22.1 
(Fig. 6o, s, u). Overall, CBTAU-22.1 showed partial overlap 
with AT8 and CBTAU-7.1 and was primarily confined to 
more dense or aggregated structures, again indicating that 
CBTAU-22.1 is more selective for IHC detection of neu-
rofibrillary changes. Both CBTAU-7.1 and CBTAU-22.1 
also show immunoreactivity of pathological tau structures 
in primary age-related tauopathy (PART) [13], progressive 
supranuclear palsy (PSP), frontotemporal dementia with 
microtubule-associated tau gene mutation (FTDP-17) and 
Pick’s disease cases, indicating that the phospho-epitopes 
detected by CBTAU-7.1 and CBTAU-22.1 are present 
throughout different tauopathies (Fig. S9). Consistent with 
our observations in AD brain tissue, CBTAU-7.1 showed a 
comparable immunostaining as observed with AT8, while 
CBTAU-22.1 showed immunostaining of dense pathologi-
cal structures in different tauopathies.
Discussion
Using a high-throughput, single-cell, screening methodol-
ogy, we were able to recover a panel of 52 tau antibodies 
from the memory B cell compartment of healthy individu-
als between the ages of 18 and 66. Although we cannot dis-
tinguish whether antibodies recovered from the same pool 
of (up to four) donors arose from one or different donors 
based on the screening strategy we used, it would appear 
that a tau-reactive IgG response is not an uncommon fea-
ture in the healthy donor population screened. This result 
is in accordance with previous reports of the presence of 
naturally occurring antibodies to tau in sera of healthy indi-
viduals [29, 48, 54, 55]. A higher than expected proportion 
Fig. 6  Double immunostaining with AT8, CBTAU-7.1 and CBTAU-
22.1. Double immunostaining was performed on 5 μm-thick slide-
mounted formalin-fixed, paraffin-embedded sections (temporal 
cortex, Alzheimer’s disease case, Braak VI). Double staining was 
analyzed with a spectral camera and digitally unmixed. Single stain-
ing patterns are presented separately (gray scale) and merged in 
artificial fluorescent colors. (a–f) Double immunostaining with AT8 
(0.25 μg/ml, chromogen liquid permanent red, LPR) and CBTAU-7.1 
(2.5 μg/ml, chromogen DAB). Areas indicated with dotted lines in a, 
c, and e are shown in higher magnification in b, d, and f respectively. 
(g–o) Double immunostaining with AT8 (0.25 μg/ml, LPR) and 
CBTAU-22.1 (10 μg/ml DAB). Areas indicated with dotted lines in g, 
j, and m are shown in higher magnification in h/i, k/l, and n/o respec-
tively. (p–u); Double immunostaining with CBTAU-7.1 (2.5 μg/ml, 
LPR) and CBTAU-22.1 (10 μg/ml, DAB). Areas indicated with dot-
ted lines in p, r, and t are shown in higher magnification in q, s, and 




of the recovered antibodies was derived from the IGHV3 
gene family. Similar heavy chain germline preferences 
have been previously reported for other targets. For exam-
ple, a higher than expected proportion of influenza hemag-
glutinin stem binders appear to utilize the VH1-69 germline 
[12, 56, 58, 63], and this preference may reflect the ability 
of particular germline sequences to solve specific recogni-
tion problems [37, 38, 45].
The tau antibodies recognize a variety of epitopes across 
tau and binding of 26 of these antibodies is strictly depend-
ent on the presence of phosphorylated residues in their 
respective epitopes. Thirteen antibodies showed activity in 
an in vitro aggregation assay and, although activity is not 
limited to antibodies that recognize phosphorylated tau, it is 
notable that all (eight of eight) phospho-dependent antibod-
ies that bind to the C-terminus of tau show activity. Since 
anti-tau antibodies that block tau aggregate seeding in vitro 
have been shown to decrease pathology and improve cogni-
tion in a mouse model of AD [65], these results suggest that 
this region may be of particular interest as a target for ther-
apy. Potential explanations for the apparent low potency 
of the set of human anti-tau mAbs compared to AT8 in the 
in vitro aggregation assay may be lower affinity for the 
seeds present in P301S spinal cord lysates or recognition of 
only a subset of these seeds, which may be caused by pref-
erential recognition of additional post-translational modifi-
cations (e.g., acetylation), specific tau isoforms, or certain 
conformations of misfolded and aggregated tau. Further 
characterization of the antibodies should shed light on this 
issue. It would also be of interest to assess the ability of 
these human anti-tau antibodies to promote uptake of tau 
aggregates by microglia, which represents an Fc-mediated 
mechanism of action [19].
Two antibodies, CBTAU-7.1 and CBTAU-22.1, were 
studied in more detail as representatives for antibodies with 
activity in the in vitro tau aggregate seeding assay binding 
to distinct regions of tau. Both antibodies were consider-
ably less potent in this assay than murine antibody AT8 
(Fig. S2), which can likely be explained by a lower affinity 
for tau, as indicated by the relatively low affinity for their 
respective cognate peptides (Fig. S3). However, our West-
ern blot and IP-MS data indicate that both antibodies are in 
fact directed against some species of tau and both appear to 
specifically stain tau structures in human brain by immuno-
histochemistry. Both CBTAU-7.1 and CBTAU-22.1 detect 
various pathological tau structures in AD brain tissue and 
selectively detect a phosphorylated epitope of tau in tissue. 
Crystal structures of both CBTAU-7.1 and CBTAU-22.1 
revealed multiple positively charged arginine and lysine 
residues in the combining sites that are likely to be impor-
tant for the recognition of the phosphate groups in the phos-
phorylated peptide epitopes in tau, as in other structurally 
characterized anti-tau antibodies such as pT231/pS235_1 
with phosphorylated peptide pT231/pS235 [52], RB86 
with phosphorylated peptide (416–430) [10] and AT8 with 
phosphorylated peptide (202–209) [40]. While CBTAU-7.1 
binds the same region of tau as murine anti-PHF antibody 
AT8, it recognizes a slightly different epitope. In particular, 
CBTAU-7.1 appears to be more promiscuous with respect 
to the exact residues that need to be phosphorylated and 
may thus recognize a wider spectrum of phosphorylated 
tau species. However, CBTAU-7.1 shows similar detection 
of pathological structures compared to AT8 and follows 
a similar distribution throughout different Braak stages 
(Fig. S8). In contrast, CBTAU-22.1 immunostaining on 
AD brain tissue is confined to more dense or aggregated 
tau structures and shows comparable detection as obtained 
with the Gallyas staining of neurofibrillary changes. As the 
Gallyas staining is still the gold standard for the detection 
of neurofibrillary changes and neuropathological diagnosis 
of AD, it would be interesting to investigate the CBTAU-
22.1 epitope for its specificity for the diagnosis of AD in a 
biomarker approach.
Our results suggest that ongoing antigen-driven immune 
responses to tau may not be an uncommon event within the 
donor population investigated. Whether these responses 
reflect changes that may predispose to, or protect against 
the development of Alzheimer’s disease remains to be 
determined. Either way, interrogating the human B cell rep-
ertoire for antibodies against modified (pathogenic) forms 
of tau can identify antibodies that may provide further 
insights into the underlying disease processes and potential 
intervention strategies. In particular, interrogating the mem-
ory B cell repertoire in human cohorts that are well defined 
in terms of age and health status (e.g., young vs elderly and 
healthy vs AD) would be of interest. For example, immuno-
sequencing the antibody repertoires of such cohorts may 
lead to the identification of immune signatures that distin-
guish healthy individuals from individuals with (prodro-
mal) AD. In addition, assays able to detect potential dif-
ferences in antibody profiles (in either serum or CSF) may 
be able to distinguish healthy from AD. Given the range of 
anti-tau specificities found in the current study, such anti-
body assays should be able to measure the response against 
as many different tau epitopes as possible. Various studies 
have described the use of the presence of tau fragments in 
CSF [24, 31, 34, 53] and plasma [27, 30] as marker for the 
diagnosis of AD. Recent studies by Meredith et al. [44] and 
Barthélemy et al. [6] show that some fragments are signifi-
cantly more abundant than others and that discrimination 
of AD from control is dependent on the subset of tau spe-
cies measured [44]. However, current immunoassays are 
limited by a lack of available tau antibodies and measure 
only a limited range of tau species [6, 44]. Therefore, the 
presence of tau-specific antibodies in the human immune 
repertoire may provide a valuable source of antibodies that 
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may be exploited for the development of antigen assays 
with increased resolution in terms of the tau species that 
can be measured thereby allowing for the development of 
more robust AD biomarkers. Finally, the diagnostic and 
predictive potential of any novel antibody- or antigen assay 
will need to be validated in cross-sectional and longitudinal 
cohort studies.
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